Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy

Guptill, Jeffrey T.; Bromberg, Mark B.; Zhu, Li; Sharma, Bal Krishan; Thompson, Amy R.; Krueger, Andrew; Sanders, Donald B.

doi:10.1002/mus.24109

Cited by 25 publications

(33 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(23%). Guptill et al . calculated direct costs of CIDP patients using health plan paid costs in the United States from 2011.…”

Section: Discussionmentioning

confidence: 99%

“…IVIg is an effective treatment in CIDP, and IVIg and corticosteroids are considered first‐line therapies in CIDP . Randomized‐dose comparative studies to determine the best dosage and treatment intervals with IVIg are important to optimize treatment for patients and justify its cost‐intensive use in the long‐term management of CIDP …”

Section: Discussionmentioning

confidence: 99%

“…Available studies reported high total COI of CIDP (€20,650-€39,752 per year) and identified treatment with commercially available intravenous immunoglobulins (IVIg) as the most important determinant of costs. 3,4 However, both studies lacked adequate clinical evaluation of patients, and data on predictors of costs are limited to a correlation of disability with total disease costs. 4 Given that healthcare resources are finite, comprehensive studies on costs of CIDP are essential.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Costs of illness in chronic inflammatory demyelinating polyneuropathy in Germany

Mengel

Fraune

Sommer³

et al. 2018

Muscle and Nerve

View full text Add to dashboard Cite

show abstract

“…(23%). Guptill et al . calculated direct costs of CIDP patients using health plan paid costs in the United States from 2011.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Costs of illness in chronic inflammatory demyelinating polyneuropathy in Germany

Mengel

Fraune

Sommer³

et al. 2018

Muscle and Nerve

View full text Add to dashboard Cite

show abstract

“…IVIg represented 90% of pharmacy costs, the major cost drivers, accounting for 57% of total expenditure. 34 These findings all unequivocally demonstrate the amplitude of the financial impact of immunoglobulin therapy and the importance of optimizing its use.…”

Section: Ivig For Cidp: Economic Issuesmentioning

confidence: 91%

Long‐term Immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy

Rajabally

2015

Muscle and Nerve

View full text Add to dashboard Cite

Immunoglobulins are an effective but expensive treatment for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Although the goal is to improve function, use of functional scales to monitor therapy is not widespread. Limited recent evidence suggests that doses lower than those used traditionally may be as effective. There are no proven correlations of effective dose with weight, disease severity, or duration. The clinical course of CIDP is heterogeneous and includes monophasic forms and complete remissions. Careful monitoring of immunoglobulin use is necessary to avoid overtreatment. Definitive evidence for immunoglobulin superiority over steroids is lacking. Although latest trial evidence favors immunoglobulins over steroids, the latter may result in higher remission rates and longer remission periods. This article addresses the appropriateness of first-line, high-dose immunoglobulin treatment for CIDP and reviews important clinical questions regarding the need for long-term therapy protocols, adequate monitoring, treatment withdrawal, and consideration of corticosteroids as an alternative to immunoglobulin therapy.

show abstract

“…Most patients with CIDP require maintenance treatment for years or even decades [8]. CIDP is therefore a disabling disorder with a considerable impact on patients and patient-related health care costs [9][10][11][12][13][14]. However, the population-based burden and related health costs are unknown.…”

Section: Introductionmentioning

confidence: 99%

Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis

et al. 2019

View full text Add to dashboard Cite

Background: Prevalence and incidence rates of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are required to determine the impact of CIDP on society. We aimed to estimate the prevalence and incidence of CIDP worldwide and to determine the effect of diagnostic criteria on prevalence and incidence. Method: A systematic review was conducted for all published incidence and prevalence studies on CIDP until May 18, 2017. Methodological quality was assessed using the Methodological Evaluation of Observational Research checklist. We performed a random effect meta-analysis to estimate pooled prevalence and incidence rates. Results: Of the 907 studies, 11 were included in the systematic review, 5 in the meta-analysis of incidence (818 cases; 220,513,514 person-years) and 9 in the meta-analysis of prevalence (3,160 cases; 160,765,325 population). These studies had a moderate quality. The pooled crude incidence rate was 0.33 per 100,000 person-years (95% CI 0.21–0.53; I² = 95.7%) and the pooled prevalence rate was 2.81 per 100,000 (95% CI 1.58–4.39; I² = 99.1%). Substantial heterogeneity in incidence and prevalence across studies seems to be partly explained by using different diagnostic criteria. Conclusion: These findings provide a starting point to estimate the social burden of CIDP and demonstrate the need to reach consensus on diagnostic criteria for CIDP.

show abstract

Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy

Abstract: Healthcare costs for CIDP patients are substantial, with a large burden in pharmacy usage. Studies are needed to determine optimal long-term treatment strategies for CIDP, particularly related to IVIg.

Cited by 25 publications

References 19 publications

Costs of illness in chronic inflammatory demyelinating polyneuropathy in Germany

Costs of illness in chronic inflammatory demyelinating polyneuropathy in Germany

Long‐term Immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy

Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About